Add To Watchlist
Share URL
About The Company
CEO
Mr. Christopher A. Viehbacher
Market Cap
28.26 Billion USD
Sector
Healthcare
Website
https://www.biogen.comLast Update
2/22/2024, 12:00:00 PM
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
Read More
Overview
Value
51
Growth
44
Health
60
Management
74
Analyst Opinion
80
Total
56
All Scores Out Of 100
Best Features
- Has a low level of debt
- Has a history of share buybacks
- Low risk of bankruptcy
- Has strong financial health
- Has a margin-of-safety above fair value
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Earnings have declined recently
- Disliked by Twitter users
- Price-to-earnings ratio of 27.3 is higher than the market average (19.6x)
- Dividend could be at risk
Market Peers
BIIB
Key Figures
PE Ratio (TTM)
27.35
Margin Of Safety (DCF)
122.17%
Revenue Growth (5 Year Average)
0.20%
Ratings Consensus
Buy
Share Buybacks
6.85%
Dividend Yeild (TTM)
0.00%
Valuation
Value Score
51
- ✔ Margin-of-safety of 122.17% is better than the market average (17.95%)
- ✔ Estimated intrinsic-value of 487.92 USD is higher than current price ( 194.38 USD)
- ✘ Price-to-earnings ratio of 27.3 is higher than the market average (19.6x)
- ✘ Free-cashflow-yeild of 3.87% is worse than the market average (4.7%)
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 502.1 USD ✔
Current Price: 219.6 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
27.35x
Free Cashflow Yeild
3.87%
PE/Earnings Growth
0.29
Price/Book
2.16x
Growth
Growth Score
44
- ✔ 5 Year Average Earnings growth of 22.83% is higher than the market average (14.48%)
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of 0.20% is lower than the market average (10.97%)
- ✘ Revenue growth has slowed this year
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 3.56% is lower than the market average (12.35%)
Revenue Growth
0.20%
Earnings Growth
22.83%
Cashflow Growth
3.56%
Health
Health Score
60
Altman Z Score
3.30
Piostroski Score
4.00
Debt/Equity
0.49x
Current Assets/Liabilities
2.99x
Free Cashflow/Total Debt
0.25x
Debt/Capital
0.68x
Dividend
Secure Dividend Score
0
- ✔ Long term dividend payout ratio of 0.00% is considered good
- ✔ Payout ratio (TTM) of 0.00% is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Dividend yeild of 0.00% is less than the market average (1.85%)
- ✘ Very unsafe
Dividend Yeild
0.00%
Dividend Growth
0.00%
Payout Ratio (Earnings)
0.00%
Payout Ratio (Cashflow)
0.00%
Management
Management Score
74
Average Buybacks/Dilution
6.85%
Recent Buybacks/Dilution
-2.51%
5 Year Price Volitility
16.25%
Return On Assets
12.10%
Return On Capital Employed
16.95%
Return On Equity
22.18%
Return On Free Cashflow
N/A
Return On Investments
136.34%
Analysts
Analyst Opinion
80
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Biogen Inc.
Currency
USD
Beta
0.144467
Vol Avg
1163943
Ceo
Mr. Christopher A. Viehbacher
Cik
0000875045
Cusip
09062X103
Exchange
NASDAQ Global Select
Full Time Employees
8725
Industry
Drug Manufacturers—General
Sector
Healthcare
Ipo Date
1991-09-17
Address
225 Binney Street
City
Cambridge
State
MA
Country
US
Zip
02142
Phone
617 679 2000
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
28
Twitter Sentiment
0.00
Stocktwits Sentiment
55.00